

What is claimed is:

1. An inhibiting agent of the proliferation of vascular smooth muscles, comprising 14-membered ring macrolide compounds as an active ingredient.
2. An inhibiting agent according to Claim 1 wherein the vascular smooth muscles are human coronary vascular smooth muscles.
3. An inhibiting agent according to Claim 1 or 2 wherein the 14 -membered ring macrolide compounds are selected from erythromycin or its derivatives, or roxithromycin or its derivatives.
4. An inhibiting agent according to Claim 3 wherein the 14-membered ring macrolide compound is roxithromycin.
5. A potentiating agent of the expression of cyclin-dependent kinase complex (CDKIs-27), comprising 14-membered ring macrolide compounds as an active ingredient.
6. A potentiating agent according to Claim 5 wherein the 14-membered ring macrolide compounds are selected from erythromycin or its derivatives, or roxithromycin or its derivatives.
7. A potentiating agent according to Claim 6 wherein the 14-membered ring macrolide compound is roxithromycin.
8. A preventive and/or therapeutic agent for diseases caused by the proliferation or growth of vascular smooth muscles, comprising 14-membered ring macrolide compounds as an active ingredient.
9. A preventive and/or therapeutic agent according to Claim 8 wherein the disease caused by the proliferation or growth of vascular smooth muscles is arteriosclerosis or chronic vascular sclerosis concurrent with the proliferation or growth of vascular smooth muscles.
10. A preventive and/or therapeutic agent according to Claim 8 wherein the disease caused by the proliferation or growth of vascular smooth muscles is cerebrovascular stenosis, renovascular stenosis, or myocardial infarction.
11. A preventive and/or therapeutic agent according to one of Claims 8 ~10 wherein the 14-membered ring macrolide compounds are selected from erythromycin or its derivatives, or roxithromycin or its derivatives.
12. A preventive and/or therapeutic agent according to Claim 11 wherein the 14-membered ring macrolide compound is roxithromycin.
13. A method for the inhibition of the proliferation or growth of vascular smooth muscles, comprising administrating a therapeutically effective amount of

14-membered ring macrolide compounds.

14. A method according to Claim 13 wherein a stage from G1 phase to S phase in a cell cycle is significantly inhibited.

15. A method according to Claim 14 wherein the inhibition of the stage from G1 phase to S phase in a cell cycle is caused by inhibition of production of phosphorylated retinoblastoma gene products.

16. A method according to Claim 14 or 15 wherein the inhibition of the stage from G1 phase to S phase in a cell cycle is caused by potentiation of the expression of cyclin-dependent kinase complex (CDKIs-p27).

10 17. A method for the treatment of diseases caused by the proliferation or growth of vascular smooth muscles, comprising administrating a therapeutically effective amount of the 14-membered ring macrolide compounds.

18. A method for the prevention of re-obstruction after the operation of obstruction in cardiac coronary artery, comprising administrating a 15 preventively effective amount of the 14-membered ring macrolide compounds.

19. A method according to one of Claims 13~18 wherein the administration is done orally.

20 20. A method according to one of Claims 13~19 wherein the 14-membered ring macrolide compounds are selected from erythromycin or its derivatives, or roxithromycin or its derivatives.

21. A method according to Claim 20 wherein the 14-membered ring macrolide compound is roxithromycin.